Initial results indicate for the first time a meaningful clinical benefit among high-risk multiple myeloma patients, who typically relapse within a year of ASCT. SELLAS' lead product candidate, galinpepimut-S, was licensed from Memorial SloanKettering Cancer Center and is a late-stage innovative WT1 targeted immunotherapeutic, with the potential to treat multiple tumor types.
